Crohn’s Extension Study (M14-347)

The primary objective of this study is to evaluate the long-term efficacy, safety, and tolerability of repeated administration of adalimumab in subjects with Crohn’s disease who participated in and successfully completed Study M14-115.

The secondary objective is to assess pharmacokinetics and immunogenicity of adalimumab following subcutaneous administration.

Register Today!

Trial Information

Start DateAugust 2015
End Date2017
Trial Duration40 weeks
Number of Visits6
Lead CRCJulie Clement

For additional information
on this trial contact: